Physician profile
Arjun Ohri
NPI 1760955611
$2,972.59
in general payments reported to CMS, 2019-2025
34 companies · $1,106 in 2025
The $1,106 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $25.77 · 2022: $226 · 2023: $407 · 2024: $1,207 · 2025: $1,106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,656 · Long Term Medical Supply Or Device Loan: $49.95 · Education: $14.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,655.69 |
| Long Term Medical Supply Or Device Loan | $49.95 |
| Education | $14.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $390.39 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $387.49 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $340.22 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $313.77 | 2023-2025 | |
| Lilly USA, LLC | $186.07 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Abiomed | $161.53 | 2024 | Impella |
| Gilead Sciences, INC. | $121.05 | 2022-2025 | |
| Abbott Laboratories | $102.20 | 2024 | Freestyle Libre 3, Freestyle Insulinx |
| Bayer Healthcare Pharmaceuticals INC. | $84.38 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $74.87 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.06 | 2022-2024 | Jardiance |
| Dexcom, INC. | $60.01 | 2023-2024 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $57.42 | 2024-2025 | Gemtesa |
| Glaxosmithkline, LLC. | $56.69 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Otsuka America Pharmaceutical, INC. | $55.57 | 2023 | Nuedexta, Rexulti |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $54.60 | 2025 | Voquezna |
| Amgen INC. | $52.93 | 2024-2025 | Evenity, Prolia |
| Exact Sciences Corporation | $47.17 | 2024-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $43.53 | 2024-2025 | Gardasil 9, Capvaxive, M-M-R II |
| Sanofi-Aventis U.S. LLC | $39.53 | 2023 | |
| Genzyme Corporation | $34.49 | 2025 | |
| Organon LLC | $26.46 | 2024-2025 | Nexplanon |
| Xeris Pharmaceuticals, INC. | $22.57 | 2024 | Gvoke Hypopen |
| Regeneron Healthcare Solutions, INC. | $22.33 | 2025 | Dupixent |
| Axsome Therapeutics, INC. | $21.16 | 2024 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.35 | 2024 | Caplyta |
| Astellas Pharma US INC | $19.18 | 2025 | Veozah |
| Lundbeck LLC | $17.00 | 2025 | Rexulti |
| Eisai INC. | $16.90 | 2025 | |
| Inspire Medical Systems, INC. | $16.88 | 2025 | Inspire |
| Alkermes, INC. | $14.85 | 2024 | Vivitrol |
| Ironwood Pharmaceuticals, INC | $14.09 | 2024 | |
| Tolmar, INC. | $13.80 | 2025 | Jatenzo |
| Takeda Pharmaceuticals U.S.A., INC. | $13.05 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arjun Ohri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.